{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab",
    "query": {
      "intervention": "Canakinumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 68,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canakinumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T00:25:14.759Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01080131",
      "title": "Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Gout"
      ],
      "interventions": [
        {
          "name": "Canakinumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone acetonide 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to triamcinolone acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 226,
      "start_date": "2010-03",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2014-01-30",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 96,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01080131"
    },
    {
      "nct_id": "NCT01356602",
      "title": "Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Gouty Arthritis"
      ],
      "interventions": [
        {
          "name": "Canakinumab pre-filled syringe",
          "type": "DRUG"
        },
        {
          "name": "Canakinumab lyophilized powder",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 397,
      "start_date": "2011-05",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2014-01-29",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 69,
      "location_summary": "Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01356602"
    },
    {
      "nct_id": "NCT05984602",
      "title": "A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 9,
      "start_date": "2023-07-14",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 3,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05984602"
    },
    {
      "nct_id": "NCT04814368",
      "title": "A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LNA043",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to canakinumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-08-27",
      "completion_date": "2024-06-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 5,
      "location_summary": "La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04814368"
    },
    {
      "nct_id": "NCT00889863",
      "title": "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Juvenile Idiopathic Arthritis With Active Flare"
      ],
      "interventions": [
        {
          "name": "canakinumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "2 Years to 19 Years"
      },
      "enrollment_count": 177,
      "start_date": "2009-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2012-10-16",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00889863"
    },
    {
      "nct_id": "NCT02961218",
      "title": "Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "ACZ885",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "8 Years to 20 Years"
      },
      "enrollment_count": 49,
      "start_date": "2017-04-05",
      "completion_date": "2020-04-27",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02961218"
    },
    {
      "nct_id": "NCT04789681",
      "title": "Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Carcinoma",
        "Stage I Lung Cancer AJCC v8",
        "Stage IA1 Lung Cancer AJCC v8",
        "Stage IA2 Lung Cancer AJCC v8",
        "Stage IA3 Lung Cancer AJCC v8",
        "Stage IB Lung Cancer AJCC v8",
        "Stage II Lung Cancer AJCC v8",
        "Stage IIA Lung Cancer AJCC v8",
        "Stage IIB Lung Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-07-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04789681"
    },
    {
      "nct_id": "NCT00819585",
      "title": "A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Colchicine",
          "type": "DRUG"
        },
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matching Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matching Colchicine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 432,
      "start_date": "2008-12",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2018-07-17",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 19,
      "location_summary": "Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00819585"
    },
    {
      "nct_id": "NCT01731990",
      "title": "Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "Canakinumab (ACZ885)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 38,
      "start_date": "2012-10-30",
      "completion_date": "2016-08-04",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731990"
    },
    {
      "nct_id": "NCT00424346",
      "title": "Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2006-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2014-02-10",
      "last_synced_at": "2026-09-02T00:25:14.759Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00424346"
    }
  ]
}